// Endocrine System - Drugs
// Auto-generated from modularize-data.js

const drugs = [

    {
        "id": "insulin-lispro",
        "name": "Insulin Lispro",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Rapid-acting (15 min onset).",
        "clinicalChoice": "Mealtime coverage, rapid correction.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "insulin-regular",
        "name": "Insulin Regular",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Short-acting (30 min onset).",
        "clinicalChoice": "Mealtime coverage, DKA treatment.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes",
            "DKA"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "insulin-nph",
        "name": "Insulin NPH",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Intermediate-acting (2-4 hr onset).",
        "clinicalChoice": "Basal insulin coverage.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "insulin-glargine",
        "name": "Insulin Glargine",
        "pharmacologicClass": "insulin",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Replaces endogenous insulin, promotes glucose uptake and storage.",
        "features": "Long-acting (24 hr duration).",
        "clinicalChoice": "Once-daily basal insulin.",
        "indications": [
            "Type 1 Diabetes",
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Hypoglycemia"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "Injection site reactions"
        ],
        "interactions": "Beta-blockers mask hypoglycemia symptoms.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "metformin",
        "name": "Metformin",
        "pharmacologicClass": "biguanides",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Decrease hepatic glucose production, increase insulin sensitivity.",
        "features": "First-line therapy, weight neutral.",
        "clinicalChoice": "Initial T2DM treatment, PCOS.",
        "indications": [
            "Type 2 Diabetes",
            "PCOS"
        ],
        "contraindications": [
            "Renal Impairment",
            "Heart Failure",
            "Alcohol Abuse"
        ],
        "sideEffects": [
            "GI upset",
            "Lactic acidosis (rare)",
            "B12 deficiency"
        ],
        "interactions": "Contrast agents increase lactic acidosis risk.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "glipizide",
        "name": "Glipizide",
        "pharmacologicClass": "sulfonylureas",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Stimulate insulin release from pancreatic beta cells.",
        "features": "Short-acting, liver metabolism.",
        "clinicalChoice": "T2DM when metformin insufficient.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "SIADH"
        ],
        "interactions": "Sulfonamides potentiate effects.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "glyburide",
        "name": "Glyburide",
        "pharmacologicClass": "sulfonylureas",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Stimulate insulin release from pancreatic beta cells.",
        "features": "Long-acting, higher hypoglycemia risk.",
        "clinicalChoice": "T2DM, avoid in elderly.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Renal Impairment"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "SIADH"
        ],
        "interactions": "Sulfonamides potentiate effects.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "glimepiride",
        "name": "Glimepiride",
        "pharmacologicClass": "sulfonylureas",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Stimulate insulin release from pancreatic beta cells.",
        "features": "Once-daily dosing.",
        "clinicalChoice": "T2DM with compliance issues.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Hypoglycemia",
            "Weight gain",
            "SIADH"
        ],
        "interactions": "Sulfonamides potentiate effects.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "repaglinide",
        "name": "Repaglinide",
        "pharmacologicClass": "meglitinides",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Non-sulfonylurea insulin secretagogue. Binds to SUR1 receptor on ATP-sensitive K+ channels in pancreatic beta cells (different binding site than sulfonylureas) → closes K+ channels → membrane depolarization → Ca²⁺ influx → rapid insulin granule exocytosis. Rapid onset and short duration of action.",
        "features": "Rapid-acting insulin secretagogue, taken with meals. More potent meglitinide.",
        "clinicalChoice": "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)",
        "indications": [
            "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic ketoacidosis",
            "Gemfibrozil use (severe drug interaction - CONTRAINDICATED)",
            "Severe hepatic impairment"
        ],
        "sideEffects": [
            "Hypoglycemia (5-10%, lower than sulfonylureas)",
            "Weight gain (1-2 kg, less than sulfonylureas)",
            "Upper respiratory tract infection",
            "Headache",
            "Diarrhea"
        ],
        "interactions": "CYP3A4 and CYP2C8 interactions. Gemfibrozil CONTRAINDICATED - increases repaglinide AUC by 8-fold.",
        "interactionDetails": "GEMFIBROZIL: CONTRAINDICATED - increases repaglinide AUC by 8-fold via CYP2C8 inhibition → severe prolonged hypoglycemia. DO NOT use together.",
        "pageType": "drug"
    },
    {
        "id": "nateglinide",
        "name": "Nateglinide",
        "pharmacologicClass": "meglitinides",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Non-sulfonylurea insulin secretagogue derived from D-phenylalanine. Binds to SUR1 receptor on ATP-sensitive K+ channels in pancreatic beta cells → closes K+ channels → depolarization → Ca²⁺ influx → rapid insulin release. Fastest onset of all meglitinides.",
        "features": "Ultra-rapid onset, shortest duration. Derived from amino acid D-phenylalanine. Less potent than repaglinide.",
        "clinicalChoice": "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)",
        "indications": [
            "Type 2 Diabetes (as monotherapy or combination with metformin or TZDs)"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic ketoacidosis"
        ],
        "sideEffects": [
            "Hypoglycemia (less common than repaglinide or sulfonylureas)",
            "Weight gain (minimal, 0.5-1 kg)",
            "Upper respiratory infection",
            "Diarrhea",
            "Dizziness"
        ],
        "interactions": "CYP2C9 inhibitors (fluconazole): increase nateglinide levels slightly (monitor glucose)",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "pioglitazone",
        "name": "Pioglitazone",
        "pharmacologicClass": "thiazolidinediones",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "PPAR-γ agonists, increase insulin sensitivity in muscle and fat.",
        "features": "Improves insulin sensitivity.",
        "clinicalChoice": "T2DM with insulin resistance.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Heart Failure",
            "Bladder Cancer History"
        ],
        "sideEffects": [
            "Weight gain",
            "Fluid retention",
            "Heart failure",
            "Bone fractures"
        ],
        "interactions": "CYP2C8 inhibitors increase levels.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "rosiglitazone",
        "name": "Rosiglitazone",
        "pharmacologicClass": "thiazolidinediones",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "PPAR-γ agonist → increases insulin sensitivity in muscle and adipose tissue.",
        "features": "REMOVED FROM MARKET (2010) due to cardiovascular risk.",
        "clinicalChoice": "NOT AVAILABLE - removed from US market in 2010 due to increased risk of myocardial infarction and cardiovascular death.",
        "indications": [
            "Previously: Type 2 Diabetes (NOW WITHDRAWN FROM MARKET)"
        ],
        "contraindications": [
            "DRUG WITHDRAWN FROM MARKET",
            "Historical contraindications: Heart failure, liver disease"
        ],
        "sideEffects": [
            "Weight gain",
            "Edema",
            "Fluid retention",
            "Myocardial infarction (increased risk - reason for market withdrawal)",
            "Cardiovascular death",
            "Heart failure",
            "Bone fractures"
        ],
        "interactions": "Historical: CYP2C8/2C9 interactions similar to pioglitazone",
        "interactionDetails": "REMOVED FROM MARKET: Increased risk of myocardial infarction and cardiovascular events led to FDA restriction in 2010 and subsequent market withdrawal.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "sitagliptin",
        "name": "Sitagliptin",
        "pharmacologicClass": "dpp-4-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit dipeptidyl peptidase-4, increase incretin levels.",
        "features": "Weight neutral, low hypoglycemia risk.",
        "clinicalChoice": "T2DM add-on therapy.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Upper respiratory infections",
            "Headache",
            "Pancreatitis (rare)"
        ],
        "interactions": "Few significant interactions.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "linagliptin",
        "name": "Linagliptin",
        "pharmacologicClass": "dpp-4-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit dipeptidyl peptidase-4, increase incretin levels.",
        "features": "Hepatic elimination, safe in renal disease.",
        "clinicalChoice": "T2DM with kidney disease.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes"
        ],
        "sideEffects": [
            "Upper respiratory infections",
            "Headache",
            "Pancreatitis (rare)"
        ],
        "interactions": "Few significant interactions.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "exenatide",
        "name": "Exenatide",
        "pharmacologicClass": "glp-1-receptor-agonists",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Mimic incretin hormones, glucose-dependent insulin release.",
        "features": "Twice-daily injection, weight loss.",
        "clinicalChoice": "T2DM with obesity.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Gastroparesis"
        ],
        "sideEffects": [
            "Nausea",
            "Vomiting",
            "Diarrhea",
            "Pancreatitis risk"
        ],
        "interactions": "Delay gastric emptying, affect oral drug absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "liraglutide",
        "name": "Liraglutide",
        "pharmacologicClass": "glp-1-receptor-agonists",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Mimic incretin hormones, glucose-dependent insulin release.",
        "features": "Once-daily, cardiovascular benefits.",
        "clinicalChoice": "T2DM with CV risk.",
        "indications": [
            "Type 2 Diabetes",
            "Obesity"
        ],
        "contraindications": [
            "MTC History",
            "MEN 2"
        ],
        "sideEffects": [
            "Nausea",
            "Vomiting",
            "Diarrhea",
            "Pancreatitis risk"
        ],
        "interactions": "Delay gastric emptying, affect oral drug absorption.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "empagliflozin",
        "name": "Empagliflozin",
        "pharmacologicClass": "sglt2-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Block sodium-glucose cotransporter-2 in kidneys, increase glucose excretion.",
        "features": "Cardiovascular and renal benefits.",
        "clinicalChoice": "T2DM with heart failure or CKD.",
        "indications": [
            "Type 2 Diabetes",
            "Heart Failure"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Severe Renal Impairment"
        ],
        "sideEffects": [
            "UTIs",
            "Genital mycotic infections",
            "DKA risk",
            "Dehydration"
        ],
        "interactions": "Diuretics increase dehydration risk.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "canagliflozin",
        "name": "Canagliflozin",
        "pharmacologicClass": "sglt2-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Block sodium-glucose cotransporter-2 in kidneys, increase glucose excretion.",
        "features": "May reduce CV events.",
        "clinicalChoice": "T2DM with established CVD.",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Severe Renal Impairment",
            "Lower Limb Amputation History"
        ],
        "sideEffects": [
            "UTIs",
            "Genital mycotic infections",
            "DKA risk",
            "Dehydration"
        ],
        "interactions": "Diuretics increase dehydration risk.",
        "interactionDetails": "",
        "pageType": "drug"
    },
    {
        "id": "pramlintide",
        "name": "Pramlintide",
        "pharmacologicClass": "amylin-analogs",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Synthetic analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. Slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety via central mechanisms.",
        "features": "Only amylin analog available. Adjunct to insulin therapy.",
        "clinicalChoice": "For patients on mealtime insulin who have inadequate glucose control despite optimal insulin therapy. Unique benefit of weight loss (3-4 kg average).",
        "indications": [
            "Type 1 Diabetes (as adjunct to mealtime insulin)",
            "Type 2 Diabetes (as adjunct to mealtime insulin)"
        ],
        "contraindications": [
            "Gastroparesis",
            "Hypoglycemia unawareness"
        ],
        "sideEffects": [
            "Nausea (60-70%, usually improves over 4 weeks)",
            "Vomiting",
            "Anorexia",
            "Headache",
            "Severe hypoglycemia (when not reducing insulin dose appropriately)"
        ],
        "interactions": "Insulin: increased hypoglycemia risk (reduce insulin dose by 50%). Drugs requiring rapid absorption: delayed by pramlintide.",
        "interactionDetails": "BLACK BOX: Severe hypoglycemia - must reduce mealtime insulin by 50% when starting pramlintide.",
        "pageType": "drug"
    },
    {
        "id": "acarbose",
        "name": "Acarbose",
        "pharmacologicClass": "alpha-glucosidase-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Reversibly inhibits alpha-glucosidase enzymes in small intestine brush border, delaying breakdown of complex carbohydrates into absorbable monosaccharides. Reduces postprandial glucose spikes.",
        "features": "Minimal systemic absorption (<2%). Acts locally in GI tract.",
        "clinicalChoice": "For patients with elevated postprandial glucose but acceptable fasting glucose. Particularly useful in Asian populations (high-carbohydrate diets).",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Inflammatory bowel disease (Crohn's, ulcerative colitis)",
            "Colonic ulceration",
            "Intestinal obstruction",
            "Chronic intestinal diseases with malabsorption",
            "Cirrhosis"
        ],
        "sideEffects": [
            "Flatulence (75% of patients - due to colonic fermentation of undigested carbs)",
            "Diarrhea (30%)",
            "Abdominal pain/cramping (20%)",
            "Elevated liver enzymes (rare, reversible)"
        ],
        "interactions": "Must take with FIRST BITE of meal. If hypoglycemia occurs, treat with GLUCOSE (not sucrose - acarbose blocks sucrose breakdown).",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "miglitol",
        "name": "Miglitol",
        "pharmacologicClass": "alpha-glucosidase-inhibitors",
        "therapeuticClass": "diabetes-medications",
        "system": "endocrine-system",
        "mechanism": "Reversibly inhibits alpha-glucosidase enzymes in small intestine, delaying digestion and absorption of carbohydrates. Reduces postprandial glucose excursions.",
        "features": "Well absorbed systemically (unlike acarbose). Renally excreted unchanged.",
        "clinicalChoice": "Alternative to acarbose with similar efficacy and side effect profile. Avoid in renal impairment (systemically absorbed and renally excreted).",
        "indications": [
            "Type 2 Diabetes"
        ],
        "contraindications": [
            "Inflammatory bowel disease",
            "Colonic ulceration",
            "Intestinal obstruction",
            "Severe renal impairment (CrCl <25 mL/min)",
            "Chronic intestinal diseases with malabsorption"
        ],
        "sideEffects": [
            "Flatulence (70% - due to colonic fermentation)",
            "Diarrhea (30%)",
            "Abdominal pain (10-15%)"
        ],
        "interactions": "Must take with FIRST BITE of each meal. If hypoglycemia occurs, treat with GLUCOSE (not sucrose).",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "levothyroxine",
        "name": "Levothyroxine",
        "pharmacologicClass": "thyroid-hormones",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Replace deficient thyroid hormones T4 and T3.",
        "features": "T4 replacement, converted to T3.",
        "clinicalChoice": "Hypothyroidism treatment.",
        "indications": [
            "Hypothyroidism",
            "Thyroid Cancer"
        ],
        "contraindications": [
            "Untreated Adrenal Insufficiency"
        ],
        "sideEffects": [
            "Hyperthyroid symptoms",
            "Arrhythmias",
            "Osteoporosis"
        ],
        "interactions": "Iron, calcium reduce absorption.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "liothyronine",
        "name": "Liothyronine",
        "pharmacologicClass": "thyroid-hormones",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Replace deficient thyroid hormones T4 and T3.",
        "features": "T3 replacement, rapid onset.",
        "clinicalChoice": "Myxedema coma.",
        "indications": [
            "Severe Hypothyroidism",
            "Myxedema Coma"
        ],
        "contraindications": [
            "Untreated Adrenal Insufficiency"
        ],
        "sideEffects": [
            "Hyperthyroid symptoms",
            "Arrhythmias",
            "Osteoporosis"
        ],
        "interactions": "Iron, calcium reduce absorption.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "methimazole",
        "name": "Methimazole",
        "pharmacologicClass": "antithyroid-agents",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit thyroid hormone synthesis.",
        "features": "Preferred agent, once-daily dosing.",
        "clinicalChoice": "Hyperthyroidism treatment.",
        "indications": [
            "Hyperthyroidism",
            "Graves Disease"
        ],
        "contraindications": [
            "Pregnancy (1st trimester)"
        ],
        "sideEffects": [
            "Agranulocytosis",
            "Hepatotoxicity",
            "Rash"
        ],
        "interactions": "Warfarin effects enhanced.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "propylthiouracil",
        "name": "Propylthiouracil",
        "pharmacologicClass": "antithyroid-agents",
        "therapeuticClass": "thyroid-medications",
        "system": "endocrine-system",
        "mechanism": "Inhibit thyroid hormone synthesis.",
        "features": "Blocks T4 to T3 conversion.",
        "clinicalChoice": "Pregnancy, thyroid storm.",
        "indications": [
            "Hyperthyroidism in Pregnancy",
            "Thyroid Storm"
        ],
        "contraindications": [
            "Severe Liver Disease"
        ],
        "sideEffects": [
            "Agranulocytosis",
            "Hepatotoxicity",
            "Rash"
        ],
        "interactions": "Warfarin effects enhanced.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "prednisone",
        "name": "Prednisone",
        "pharmacologicClass": "glucocorticoids",
        "therapeuticClass": "corticosteroids",
        "system": "endocrine-system",
        "mechanism": "Anti-inflammatory and immunosuppressive effects via genomic pathways.",
        "features": "Oral prodrug, converted to prednisolone. | Oral, intermediate-acting.",
        "clinicalChoice": "Inflammatory conditions, immunosuppression.",
        "indications": [
            "Allergic Reactions",
            "Asthma",
            "Autoimmune Disorders",
            "Inflammatory Diseases",
            "Rheumatoid Arthritis"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Hyperglycemia",
            "Osteoporosis",
            "Immunosuppression",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers/inhibitors affect levels.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug",
        "pharmacologicClasses": [
            "glucocorticoids",
            "systemic-corticosteroids"
        ]
    },
    {
        "id": "dexamethasone",
        "name": "Dexamethasone",
        "pharmacologicClass": "glucocorticoids",
        "therapeuticClass": "corticosteroids",
        "system": "endocrine-system",
        "mechanism": "Anti-inflammatory and immunosuppressive effects via genomic pathways.",
        "features": "Long-acting, high potency. | Long-acting, potent, minimal mineralocorticoid activity.",
        "clinicalChoice": "Cerebral edema, severe inflammation.",
        "indications": [
            "Adrenal Insufficiency Testing",
            "Cerebral Edema",
            "Severe Asthma"
        ],
        "contraindications": [
            "Systemic Fungal Infections"
        ],
        "sideEffects": [
            "Hyperglycemia",
            "Osteoporosis",
            "Immunosuppression",
            "Adrenal suppression"
        ],
        "interactions": "CYP3A4 inducers/inhibitors affect levels.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug",
        "pharmacologicClasses": [
            "glucocorticoids",
            "systemic-corticosteroids"
        ]
    },
    {
        "id": "fludrocortisone",
        "name": "Fludrocortisone",
        "pharmacologicClass": "mineralocorticoids",
        "therapeuticClass": "corticosteroids",
        "system": "endocrine-system",
        "mechanism": "Sodium retention and potassium excretion in distal nephron.",
        "features": "Oral mineralocorticoid replacement.",
        "clinicalChoice": "Adrenal insufficiency with salt wasting.",
        "indications": [
            "Primary Adrenal Insufficiency",
            "Orthostatic Hypotension"
        ],
        "contraindications": [
            "Systemic Fungal Infections",
            "Hypertension"
        ],
        "sideEffects": [
            "Hypertension",
            "Hypokalemia",
            "Fluid retention"
        ],
        "interactions": "NSAIDs reduce effectiveness.",
        "interactionDetails": "",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "semaglutide",
        "name": "Semaglutide",
        "pharmacologicClass": "glp-1-agonists",
        "therapeuticClass": "diabetes",
        "system": "endocrine-system",
        "mechanism": "GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, promotes satiety.",
        "features": "Once-weekly injectable or daily oral, significant weight loss (10-15%), proven CV benefits.",
        "clinicalChoice": "Type 2 diabetes with obesity or established CV disease, weight management.",
        "indications": [
            "Type 2 Diabetes Mellitus",
            "Obesity/Weight Management",
            "Cardiovascular Risk Reduction"
        ],
        "contraindications": [
            "Personal/family history of medullary thyroid carcinoma",
            "MEN 2 syndrome",
            "Pancreatitis history"
        ],
        "sideEffects": [
            "Nausea/vomiting (common, dose-dependent)",
            "Diarrhea",
            "Pancreatitis (rare)",
            "Thyroid C-cell tumors (animal studies)",
            "Gastroparesis",
            "Gallstones"
        ],
        "interactions": "Delays gastric emptying (affects oral drug absorption), insulin/sulfonylureas (hypoglycemia risk).",
        "interactionDetails": "ORAL MEDICATIONS: MECHANISM - Semaglutide delays gastric emptying, potentially reducing absorption of oral medications. CONSEQUENCE - May affect timing and absorption of oral drugs, especially those requiring rapid absorption. INSULIN/SULFONYLUREAS: MECHANISM - Additive glucose-lowering effects. CONSEQUENCE - Increased hypoglycemia risk. Reduce insulin or sulfonylurea dose when initiating semaglutide.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "dulaglutide",
        "name": "Dulaglutide",
        "pharmacologicClass": "glp-1-agonists",
        "therapeuticClass": "diabetes",
        "system": "endocrine-system",
        "mechanism": "GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.",
        "features": "Once-weekly subcutaneous injection, single-use pen.",
        "clinicalChoice": "Type 2 diabetes requiring injectable therapy, CV risk reduction.",
        "indications": [
            "Type 2 Diabetes Mellitus",
            "Cardiovascular Risk Reduction"
        ],
        "contraindications": [
            "Personal/family history of medullary thyroid carcinoma",
            "MEN 2 syndrome"
        ],
        "sideEffects": [
            "Nausea/vomiting",
            "Diarrhea",
            "Abdominal pain",
            "Pancreatitis (rare)",
            "Injection site reactions"
        ],
        "interactions": "Delays gastric emptying (affects oral drug absorption), insulin/sulfonylureas (hypoglycemia).",
        "interactionDetails": "Similar to semaglutide - delays gastric emptying affecting oral drug absorption. Additive hypoglycemia risk with insulin or sulfonylureas requiring dose adjustment.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "dapagliflozin",
        "name": "Dapagliflozin",
        "pharmacologicClass": "sglt2-inhibitors",
        "therapeuticClass": "diabetes",
        "system": "endocrine-system",
        "mechanism": "Inhibit SGLT2 in proximal tubule, preventing glucose reabsorption and causing glucosuria.",
        "features": "Additional heart failure and CKD benefits beyond glucose control.",
        "clinicalChoice": "Type 2 diabetes with heart failure, CKD, or ASCVD.",
        "indications": [
            "Type 2 Diabetes Mellitus",
            "Heart Failure (HFrEF and HFpEF)",
            "Chronic Kidney Disease"
        ],
        "contraindications": [
            "Severe Renal Impairment (eGFR <25)",
            "Dialysis"
        ],
        "sideEffects": [
            "Genital mycotic infections (common)",
            "UTIs",
            "Euglycemic DKA (rare but serious)",
            "Volume depletion",
            "Fournier's gangrene (rare)",
            "Acute kidney injury"
        ],
        "interactions": "Diuretics (volume depletion), insulin/sulfonylureas (hypoglycemia).",
        "interactionDetails": "DIURETICS: MECHANISM - Both SGLT2 inhibitors and diuretics cause volume loss through different mechanisms (glycosuria vs natriuresis). CONSEQUENCE - Additive volume depletion, hypotension, acute kidney injury. Monitor volume status. INSULIN/SULFONYLUREAS: MECHANISM - Additive glucose-lowering. CONSEQUENCE - Increased hypoglycemia risk, dose adjustment needed.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "saxagliptin",
        "name": "Saxagliptin",
        "pharmacologicClass": "dpp4-inhibitors",
        "therapeuticClass": "diabetes",
        "system": "endocrine-system",
        "mechanism": "Inhibit DPP-4 enzyme, increasing incretin (GLP-1, GIP) levels, enhancing glucose-dependent insulin secretion.",
        "features": "Oral, weight-neutral, low hypoglycemia risk.",
        "clinicalChoice": "Type 2 diabetes as add-on to metformin, patients unable to tolerate GLP-1 agonists.",
        "indications": [
            "Type 2 Diabetes Mellitus"
        ],
        "contraindications": [
            "Type 1 Diabetes",
            "Diabetic Ketoacidosis"
        ],
        "sideEffects": [
            "Upper respiratory infections",
            "Headache",
            "Heart failure (increased hospitalizations)",
            "Pancreatitis (rare)",
            "Severe joint pain"
        ],
        "interactions": "CYP3A4/5 inhibitors (increase saxagliptin levels), insulin/sulfonylureas (hypoglycemia).",
        "interactionDetails": "CYP3A4/5 INHIBITORS: MECHANISM - Saxagliptin metabolized by CYP3A4/5. Strong inhibitors (ketoconazole, clarithromycin) increase levels. CONSEQUENCE - Increased drug exposure. Reduce saxagliptin dose to 2.5mg with strong CYP3A4/5 inhibitors. INSULIN/SULFONYLUREAS: MECHANISM - Additive glucose-lowering. CONSEQUENCE - Hypoglycemia risk, especially with insulin or sulfonylureas.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "propranolol-thyroid",
        "name": "Propranolol (for Thyroid Storm)",
        "pharmacologicClass": "beta-blockers",
        "therapeuticClass": "thyroid-disorders",
        "systems": ["endocrine-system", "cardiovascular-system"],
        "mechanism": "Non-selective beta-blocker that blocks peripheral conversion of T4 to T3 and provides symptomatic relief (tachycardia, tremor).",
        "features": "Unique among beta-blockers for blocking T4→T3 conversion, critical for thyroid storm.",
        "clinicalChoice": "Thyroid storm (emergency), symptomatic hyperthyroidism.",
        "indications": [
            "Thyroid Storm",
            "Hyperthyroidism (symptomatic relief)",
            "Hypertension",
            "Migraine Prophylaxis"
        ],
        "contraindications": [
            "Asthma/COPD",
            "Severe Bradycardia",
            "Cardiogenic Shock",
            "Decompensated Heart Failure"
        ],
        "sideEffects": [
            "Bradycardia",
            "Hypotension",
            "Bronchospasm",
            "Fatigue",
            "Cold extremities",
            "Depression"
        ],
        "interactions": "Verapamil/diltiazem (severe bradycardia), epinephrine (unopposed alpha-stimulation), insulin (masks hypoglycemia).",
        "interactionDetails": "CALCIUM CHANNEL BLOCKERS: MECHANISM - Both propranolol and non-dihydropyridine CCBs have negative chronotropic and inotropic effects. CONSEQUENCE - Severe bradycardia, AV block, or heart failure. EPINEPHRINE: MECHANISM - Beta-blockade leaves alpha-receptors unopposed during epinephrine use. CONSEQUENCE - Severe hypertension and bradycardia (paradoxical response). INSULIN: MECHANISM - Beta-blockade masks hypoglycemia symptoms and impairs glycogenolysis. CONSEQUENCE - Prolonged, unrecognized hypoglycemia in diabetic patients.",
        "pageType": "drug"
    },
    {
        "id": "bromocriptine",
        "name": "Bromocriptine",
        "pharmacologicClass": "dopamine-agonists",
        "therapeuticClass": "pituitary-disorders",
        "system": "endocrine-system",
        "mechanism": "Ergot-derived dopamine D2 receptor agonist that inhibits prolactin secretion and suppresses growth hormone in acromegaly.",
        "features": "Oral dopamine agonist, shorter-acting than cabergoline, ergot derivative.",
        "clinicalChoice": "Prolactinoma (first-line), acromegaly (adjunct to surgery/somatostatin analogs), Parkinson's disease.",
        "indications": [
            "Prolactinoma (Hyperprolactinemia)",
            "Acromegaly",
            "Parkinson's Disease",
            "Type 2 Diabetes (quick-release formulation)"
        ],
        "contraindications": [
            "Uncontrolled Hypertension",
            "Pregnancy (for acromegaly indication)",
            "Ergot allergy"
        ],
        "sideEffects": [
            "Nausea/vomiting (common, dose-related)",
            "Orthostatic hypotension",
            "Headache",
            "Fatigue",
            "Impulse control disorders (gambling, hypersexuality)",
            "Cardiac valvulopathy (rare, with high doses)",
            "Pleuropulmonary fibrosis (rare)"
        ],
        "interactions": "Antipsychotics (antagonize dopamine effects), macrolide antibiotics (increase bromocriptine levels).",
        "interactionDetails": "ANTIPSYCHOTICS: MECHANISM - Antipsychotics (especially typical) block dopamine receptors, directly opposing bromocriptine's dopamine agonist effects. CONSEQUENCE - Reduced bromocriptine efficacy for prolactinoma or Parkinson's. Antipsychotics may also increase prolactin. Avoid combination. MACROLIDES: MECHANISM - Macrolide antibiotics (erythromycin, clarithromycin) inhibit CYP3A4, increasing bromocriptine levels. CONSEQUENCE - Enhanced side effects including hypotension, nausea, dyskinesias. Monitor closely or avoid concurrent use.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "cabergoline",
        "name": "Cabergoline",
        "pharmacologicClass": "dopamine-agonists",
        "therapeuticClass": "pituitary-disorders",
        "system": "endocrine-system",
        "mechanism": "Long-acting ergot-derived dopamine D2 receptor agonist that suppresses prolactin secretion.",
        "features": "Longer half-life (65 hours), twice-weekly dosing, better tolerated than bromocriptine.",
        "clinicalChoice": "Prolactinoma (preferred over bromocriptine - better efficacy and tolerability), hyperprolactinemia.",
        "indications": [
            "Prolactinoma (Hyperprolactinemia)",
            "Lactation Suppression (off-label)"
        ],
        "contraindications": [
            "Uncontrolled Hypertension",
            "History of Cardiac Valvulopathy",
            "Pregnancy (discontinue once pregnancy confirmed for prolactinoma)"
        ],
        "sideEffects": [
            "Nausea (less than bromocriptine)",
            "Headache",
            "Dizziness",
            "Orthostatic hypotension",
            "Impulse control disorders",
            "Cardiac valvulopathy (dose-related, monitor with echo)",
            "Hallucinations (rare)"
        ],
        "interactions": "Antipsychotics (antagonize effects), CYP3A4 inhibitors (increase levels).",
        "interactionDetails": "ANTIPSYCHOTICS: MECHANISM - Dopamine receptor blockade by antipsychotics opposes cabergoline's dopamine agonist effects. CONSEQUENCE - Reduced efficacy for prolactinoma treatment. Antipsychotics increase prolactin, counteracting therapeutic goal. Avoid combination. CYP3A4 INHIBITORS: MECHANISM - Cabergoline metabolized by CYP3A4. Inhibitors increase cabergoline levels. CONSEQUENCE - Enhanced side effects. Use lower cabergoline dose with strong CYP3A4 inhibitors.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "raloxifene",
        "name": "Raloxifene",
        "pharmacologicClass": "selective-estrogen-receptor-modulators",
        "therapeuticClass": "bone-metabolism-disorders",
        "system": "endocrine-system",
        "mechanism": "Selective estrogen receptor modulator (SERM) - estrogen agonist on bone and lipids, estrogen antagonist on breast and uterus.",
        "features": "SERM with bone protection, reduced breast cancer risk, but no uterine stimulation (unlike tamoxifen).",
        "clinicalChoice": "Postmenopausal osteoporosis prevention/treatment, breast cancer risk reduction in high-risk women.",
        "indications": [
            "Postmenopausal Osteoporosis (prevention and treatment)",
            "Breast Cancer Risk Reduction (invasive breast cancer in postmenopausal women)"
        ],
        "contraindications": [
            "Premenopausal Women",
            "Pregnancy/Lactation",
            "History of Venous Thromboembolism (VTE)",
            "Active or History of Stroke/TIA"
        ],
        "sideEffects": [
            "Hot flashes (common)",
            "Leg cramps",
            "Venous thromboembolism (DVT, PE) - 3x increased risk",
            "Stroke (increased risk)",
            "Fatal stroke (increased in women with CAD risk factors)"
        ],
        "interactions": "Cholestyramine (reduces raloxifene absorption), warfarin (decreases PT/INR).",
        "interactionDetails": "CHOLESTYRAMINE: MECHANISM - Cholestyramine binds raloxifene in GI tract, preventing absorption. CONSEQUENCE - Reduced raloxifene efficacy. Avoid concurrent use or separate dosing by several hours. WARFARIN: MECHANISM - Raloxifene may decrease warfarin absorption or enhance its metabolism. CONSEQUENCE - Decreased PT/INR, potential loss of anticoagulation. Monitor INR closely when initiating or stopping raloxifene.",
        "highYield": true,
        "pageType": "drug"
    },
    {
        "id": "teriparatide",
        "name": "Teriparatide",
        "pharmacologicClass": "parathyroid-hormone-analogs",
        "therapeuticClass": "bone-metabolism-disorders",
        "system": "endocrine-system",
        "mechanism": "Recombinant PTH (1-34) fragment - intermittent exposure stimulates osteoblast activity more than osteoclast activity → net bone formation (anabolic).",
        "features": "Only anabolic agent for osteoporosis, increases bone density more than bisphosphonates, daily SC injection.",
        "clinicalChoice": "Severe osteoporosis with high fracture risk, osteoporosis with fragility fracture, glucocorticoid-induced osteoporosis.",
        "indications": [
            "Severe Osteoporosis (postmenopausal women, men)",
            "Glucocorticoid-Induced Osteoporosis",
            "High Fracture Risk"
        ],
        "contraindications": [
            "Paget's Disease of Bone",
            "Prior Skeletal Radiation",
            "Bone Metastases/Skeletal Malignancies",
            "Hypercalcemia",
            "Children/Young Adults (open epiphyses)"
        ],
        "sideEffects": [
            "Hypercalcemia (transient, 2-4 hours post-injection)",
            "Orthostatic hypotension/dizziness",
            "Leg cramps",
            "Nausea",
            "Osteosarcoma (BLACK BOX WARNING - seen in rats with high doses/long duration, avoid use >2 years)"
        ],
        "interactions": "Digoxin (hypercalcemia increases digoxin toxicity risk).",
        "interactionDetails": "DIGOXIN: MECHANISM - Teriparatide can cause transient hypercalcemia. Hypercalcemia increases myocardial sensitivity to digoxin and predisposes to digoxin toxicity. CONSEQUENCE - Increased risk of digoxin-induced arrhythmias. Monitor serum calcium and digoxin levels closely. Avoid concurrent use if possible.",
        "highYield": true,
        "pageType": "drug"
    }

];export default drugs;
